GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

NCT02575404 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: GR-MD-02
DRUG: Pembrolizumab

Sponsor

Providence Health & Services

Collaborators

[object Object]